OptimizeRx Corporation Q3 2025 Earnings Recap

OPRX Q3 2025 November 7, 2025

Get alerts when OPRX reports next quarter

OptimizeRx reported a robust Q3 2025 with revenues of $26.1 million, reflecting a 22% year-over-year growth, and an adjusted EBITDA of $5.1 million, exceeding expectations.

Earnings Per Share Beat

$0.20 vs $0.03 est.

+566.7% surprise

Revenue Miss

26067000 vs 30914570 est.

-15.7% surprise

Market Reaction

1-Day -17.37%

5-Day -14.73%

30-Day -25.5%

See OPRX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue guidance for FY 2025 has been raised to $105-$109 million, with adjusted EBITDA now expected between $16-$19 million.
Average revenue from the top 5 customers has grown beyond $11 million, demonstrating strong client relationships and engagement.
The company continues to reduce its debt, paying down an additional $2 million, and does not anticipate needing to access equity capital markets in the near future.
Gross margin improved to 67.2%, driven by a favorable product and channel mix, alongside disciplined cost management efforts.
Initial guidance for FY 2026 indicates revenue of $118-$124 million and adjusted EBITDA of $19-$22 million, signaling confidence in future growth.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit OPRX on AllInvestView.